COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.
作者信息
Whittle B J
机构信息
William Harvey Research Institute St Bartholomew's and the Royal London School of Medicine and Dentistry Charterhouse Square, London EC1M 6BQ, UK.
出版信息
Gut. 2000 Sep;47(3):320-5. doi: 10.1136/gut.47.3.320.
Abstract
摘要
相似文献
1
COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.肠道中的COX-1和COX-2产物：COX-2抑制剂的治疗作用
Gut. 2000 Sep;47(3):320-5. doi: 10.1136/gut.47.3.320.
2
The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.COX-1和COX-2在哮喘发病机制中的作用及其在选择性抑制剂使用中的意义。
Clin Exp Allergy. 2002 Mar;32(3):339-42. doi: 10.1046/j.1365-2222.2002.01333.x.
3
Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.选择性环氧化酶-2抑制剂作为炎症性疾病的潜在治疗药物。
Adv Exp Med Biol. 1997;407:157-61. doi: 10.1007/978-1-4899-1813-0_24.
4
COX-1 and COX-2 inhibition: current status and future perspective.环氧化酶-1与环氧化酶-2抑制作用：现状与未来展望
Acta Anaesthesiol Belg. 1998;49(3):175-83.
5
The discovery and function of COX-2.环氧化酶-2（COX-2）的发现及其功能
J Rheumatol Suppl. 1997 Jul;49:6-8.
6
The advent of highly selective inhibitors of cyclooxygenase--a review.环氧化酶高选择性抑制剂的问世——综述
Prostaglandins Other Lipid Mediat. 1998 Aug;56(5-6):341-61. doi: 10.1016/s0090-6980(98)00064-1.
7
Cyclooxygenase-2: a therapeutic target.环氧化酶-2：一个治疗靶点。
Annu Rev Med. 2002;53:35-57. doi: 10.1146/annurev.med.53.082901.103952.
8
Selective COX-2 inhibitors: are they safe for the stomach?选择性环氧化酶-2抑制剂：对胃部安全吗？
Gastroenterology. 1998 Jul;115(1):227-9. doi: 10.1016/s0016-5085(98)70388-9.
9
The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition.环氧化酶-2（COX-2）在乳腺癌中的作用及COX-2抑制的影响。
Eur J Surg Oncol. 2002 Nov;28(7):729-37. doi: 10.1053/ejso.2002.1329.
引用本文的文献
1
Anti-inflammatory drugs as potential antimicrobial agents: a review.抗炎药物作为潜在抗菌剂的综述
Front Pharmacol. 2025 Apr 8;16:1557333. doi: 10.3389/fphar.2025.1557333. eCollection 2025.
2
Comparison of the Inhibitory Effects of Flunixin Meglumine and Meloxicam on the Smooth Muscles Motility of the Gastrointestinal Tract of Cattle.氟尼辛葡甲胺和美洛昔康对牛胃肠道平滑肌运动抑制作用的比较
Vet Med Sci. 2025 Jan;11(1):e70190. doi: 10.1002/vms3.70190.
3
Recent Advances in Clinical Research for Skin Cancer Chemoprevention.皮肤癌化学预防的临床研究新进展
Cancers (Basel). 2023 Jul 27;15(15):3819. doi: 10.3390/cancers15153819.
4
Systemic Nonsteroidal Anti-Inflammatories for Analgesia in Postoperative Critical Care Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials.全身用非甾体抗炎药用于术后重症监护患者镇痛：一项随机对照试验的系统评价和荟萃分析
Crit Care Explor. 2023 Jun 28;5(7):e0938. doi: 10.1097/CCE.0000000000000938. eCollection 2023 Jul.
5
Coprecipitation of Class II NSAIDs with Polymers for Oral Delivery.用于口服给药的聚合物与II类非甾体抗炎药的共沉淀。
Polymers (Basel). 2023 Feb 15;15(4):954. doi: 10.3390/polym15040954.
6
Efficacy and safety profile of corticosteroids and non-steroidal anti-inflammatory drugs in COVID-19 management: A narrative review.皮质类固醇和非甾体抗炎药在新冠病毒疾病管理中的疗效和安全性概况：一项叙述性综述
Front Pharmacol. 2022 Dec 1;13:1063246. doi: 10.3389/fphar.2022.1063246. eCollection 2022.
7
Can Anti-inflammatory Drugs used in Plastic Surgery Procedures Increase the Risk of Hematoma?整形外科手术中使用的抗炎药物会增加血肿风险吗？
Aesthetic Plast Surg. 2023 Apr;47(2):862-871. doi: 10.1007/s00266-022-03194-x. Epub 2022 Nov 29.
8
Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease.缺血性心脏病患者使用的抗炎药物
J Clin Med. 2021 Jun 27;10(13):2835. doi: 10.3390/jcm10132835.
9
Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial.基于PRECISION试验评估塞来昔布与布洛芬和萘普生在阿联酋骨关节炎患者中的成本效益
Clinicoecon Outcomes Res. 2021 May 19;13:409-420. doi: 10.2147/CEOR.S280556. eCollection 2021.
10
Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models.锝[99mTc]标记布洛芬：使用无菌性炎症诱导动物模型的开发和生物学评价。
Mol Biol Rep. 2019 Jun;46(3):3093-3100. doi: 10.1007/s11033-019-04762-2. Epub 2019 Mar 30.
本文引用的文献
1
GASTRIC MUCOSAL INJURY BY FATTY AND ACETYLSALICYLIC ACIDS.脂肪酸和乙酰水杨酸所致的胃黏膜损伤
Gastroenterology. 1964 Mar;46:245-53.
2
3
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.塞来昔布与双氯芬酸用于类风湿关节炎长期治疗的比较：随机双盲对照研究
Lancet. 1999;354(9196):2106-11. doi: 10.1016/S0140-6736(99)02332-6.
4
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.非甾体抗炎药对血管生成的抑制作用：对癌症生长和溃疡愈合机制及影响的深入了解
Nat Med. 1999 Dec;5(12):1418-23. doi: 10.1038/70995.
5
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.与非甾体抗炎药相比，罗非昔布对上消化道的不良影响。
JAMA. 1999 Nov 24;282(20):1929-33. doi: 10.1001/jama.282.20.1929.
6
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.塞来昔布在类风湿关节炎中的抗炎及对上消化道的影响：一项随机对照试验
JAMA. 1999 Nov 24;282(20):1921-8. doi: 10.1001/jama.282.20.1921.
7
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.环氧化酶-2：药理学、生理学、生物化学及其与非甾体抗炎药治疗的相关性。
Br J Pharmacol. 1999 Nov;128(6):1121-32. doi: 10.1038/sj.bjp.0702897.
8
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.塞来昔布（一种环氧化酶-2抑制剂）治疗骨关节炎：一项随机对照试验。
Mayo Clin Proc. 1999 Nov;74(11):1095-105. doi: 10.4065/74.11.1095.
9
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.一项比较环氧化酶-2特异性抑制剂罗非昔布与布洛芬对骨关节炎患者胃十二指肠黏膜影响的随机试验。罗非昔布骨关节炎内镜研究组。
Gastroenterology. 1999 Oct;117(4):776-83. doi: 10.1016/s0016-5085(99)70334-3.
10
Aceclofenac: is the antiinflammatory effect really due to cyclooxygenase inhibition?醋氯芬酸：抗炎作用真的是由于抑制环氧化酶吗？
J Rheumatol. 1999 Sep;26(9):2064-5.
Zotero 插件